Name | N-[3-[[2-[[4-(4-Methyl-1-piperazinyl)phenyl]amino]thieno[3,2-d]pyrimidin-4-yl]oxy]phenyl]-2-propenamide |
---|---|
Synonyms |
N-{3-[(2-{[4-(4-Methyl-1-piperazinyl)phenyl]amino}thieno[3,2-d]pyrimidin-4-yl)oxy]phenyl}acrylamide
2-Propenamide, N-[3-[[2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]thieno[3,2-d]pyrimidin-4-yl]oxy]phenyl]- Olmutinib N-(3-(2-(4-(4-methylpiperazin-1-yl)phenylamino) thieno[3,2-d]pyrimidin-4-yloxy)phenyl)acrylamide HM71224 |
Description | Olmutinib (HM61713; BI-1482694) is an irreversible EGFR tyrosine kinase inhibitor that binds to a cysteine residue near the kinase domain. |
---|---|
Related Catalog | |
Target |
EGFRExon 19 deletion:9.2 nM (IC50, Cell Assay) EGFRL858R/T790M:10 nM (IC50, Cell Assay) |
In Vitro | Olmutinib potently inhibits EGFR in HCC827 cells expressing EGFRDEL19 (IC50=9.2 nM) and H1975 cells expressing EGFRL858R/T790M (IC50=10 nM). In contrast, the IC50 of olmutinib against cells expressing EGFRWT is 2225 nM[1]. |
References |
[1]. Kim ES, et al. Olmutinib: First Global Approval. Drugs.?2016 Jul;76(11):1153-7. |
Density | 1.3±0.1 g/cm3 |
---|---|
Molecular Formula | C26H26N6O2S |
Molecular Weight | 486.589 |
Exact Mass | 486.183807 |
PSA | 110.86000 |
LogP | 4.95 |
Index of Refraction | 1.706 |
Storage condition | -20℃ |